思密达加用妈咪爱治疗婴幼儿轮状病毒性肠炎228例临床观察实践

Clinical Observation and Practice of Smecta and Mamiai in the Treatment of 228 Infants with Rotavirus Enteritis

目的研究对比思密达和思密达加用妈咪爱(Mediac-vita)对于治疗婴幼儿轮状病毒性肠炎的临床疗效。方法选取我院2015年6月-2017年1月收治的228例轮状病毒性肠炎患儿进行随机分组,以随机数字表法将其分为对照组(n=114)、研究组(n=114)。对照组予以常规治疗联合思密达,研究组在对照组治疗的基础上加用妈咪爱,观察两组患儿的治疗效果、不良反应。结果研究组腹泻患儿的治疗总有效率(92.98%)高于对照组腹泻患儿的治疗总有效率(78.95%),数据比较P<0.05;两组各项药物所致不良反应对比均P>0.05。结论应用思密达联合妈咪爱治疗婴幼儿轮状病毒性肠炎有效性、安全性均较优,有利于保障患儿疗效及预后。

Objective To study and compare the clinical efficacy of Smecta and Smecta plus mediac Vita in the treatment of rotavirus enteritis in infants.Methods 228 children with rotavirus enteritis admitted in our hospital from June 2015 to January 2017 were randomly divided into control group(n=114)and study group(n=114).The control group was treated with routine therapy combined with smecta,and the study group was treated with mumianai on the basis of the control group,and the therapeutic effect and adverse reactions of the two groups were observed.Results The total effective rate(92.98%)of diarrhea in the study group was significantly higher than that in the control group(78.95%).The data comparison was P<0.05;the adverse reactions caused by various drugs in the two groups were P>0.05.Conclusion The efficacy and safety of Smecta combined with MAMIAI in the treatment of rotavirus enteritis in infants are better,which is conducive to the protection of curative effect and prognosis.